CN102429899A - Application of baicalein to preparation of medicament for treating pneumonia - Google Patents
Application of baicalein to preparation of medicament for treating pneumonia Download PDFInfo
- Publication number
- CN102429899A CN102429899A CN2011103707203A CN201110370720A CN102429899A CN 102429899 A CN102429899 A CN 102429899A CN 2011103707203 A CN2011103707203 A CN 2011103707203A CN 201110370720 A CN201110370720 A CN 201110370720A CN 102429899 A CN102429899 A CN 102429899A
- Authority
- CN
- China
- Prior art keywords
- pneumonia
- baicalein
- baicalin
- application
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to application of baicalein to preparation of a medicament for treating pneumonia. Rabbit red blood cell hemolytic tests, protection tests for human lung epithelial cell (A549) damage and mouse staphylococcus aureus pneumonia models prove that the baicalein has a treatment effect on staphylococcus aureus infection. Compared with the antibiotic treatment, the treatment using the baicalein has the characteristics of no drug resistance and high cure rate.
Description
Technical field
The present invention relates to the application of baicalin in preparation treatment pneumonia medicine, belong to field of medicaments.
One, background technology
Baicalin (Baicalein) is a kind of flavone compound that extraction separation comes out from seed of high Folium Scutellariae, Semen Oroxyli and peel of stem; Has tangible antibacterial activity; Dysentery bacterium, diphtheria corynebacterium, bacillus pyocyaneus, staphylococcus, streptococcus, Diplococcus pneumoniae and meningococcus etc. are all had inhibitory action, and minimum inhibitory concentration (MIC) is between 32-64 μ g/ml.But do not see both at home and abroad that so far baicalin is used to treat the bacterial pneumonia report.
Bacterial pneumonia is to infect caused disease by streptococcus pneumoniae, hemophilus influenza, staphylococcus aureus, micrococcus scarlatinae, legionella etc., and this disease case fatality rate in child, old people and immunodeficiency patient is high.In recent years, antibiotic a large amount of uses cause the bacterial resistance rate to increase, and make the treatment of bacterial pneumonia face the situation that pasts medical help.At present comparatively serious with the pneumonia state of an illness that staphylococcus aureus was caused clinically, especially the pneumonia case fatality rate that causes of methicillin-resistant staphylococcus aureus (MRSA) is still higher.The medicine of treatment staphylococcal pneumonia uses oxazacillin and cloxacillin usually at present, but because the appearance of MRSA usually can cause the treatment failure.Therefore, it is extremely urgent to seek novel, safe medicine.Baicalin is the composition that derives from China's Chinese medicine material Radix Scutellariae, Semen Oroxyli etc., and the present invention studies and confirmed baicalin to bacterial pneumonia, and especially the pneumonia that causes of drug resistance staphylococcus aureus has better therapeutic effect.
Two, summary of the invention
The molecular structure of baicalin is following:
It treats golden Portugal bacterium infection effect protection test and the mice gold Portugal bacterium pneumonia model validation of the present invention through the damage of rabbit erythrocyte hemolytic test, people's pulmonary epithelial cells (A549).
Three, the specific embodiment
1. hemolytic test
The alpha hemolysin of purification is done successive doubling dilution in 96 orifice plates, add 10 in each hole
7Individual rabbit erythrocyte, centrifugal after in 37 ℃, hatching 30min.Make haemoclastic highly diluted multiple be regarded as haemolysis titre (Hemolysis titre).
The haemolysis titre such as the following table 1 that do not add alpha hemolysin behind baicalin and the baicalin that adds variable concentrations:
Table 1. baicalin is to the inhibitory action of alpha hemolysin hemolytic activity
| Baicalin (μ g/ml) | Haemolysis titre (Hemolysis titre) |
| 0 | 2048 |
| 32 | 32 |
| 16 | 128 |
| 8 | 256 |
| 4 | 1024 |
2. the protection test of people's pulmonary epithelial cells (A549) damage
The gold bacterium NCTC 8325-4 of Portugal is cultured to OD in the TSB culture medium
600nm=0.5, get the bacterial cultures of 5ml, centrifugal and be resuspended in the F12K culture medium of 10ml.The A549 cell in F12K culture medium (adding 10% hyclone) in 37 ℃, 5%CO
2Cultivate after 24 hours, with 1.5 * 10
1Individual cells/well is laid in the 96 porocyte culture plates, every hole 100 μ l.Behind the cell attachment, add 100 μ l gold Portugal bacteria suspension, and add the baicalin of variable concentrations, place cell culture incubator in 37 ℃, 5%CO
2Cultivate 8h altogether.Add live (green)/dead (red) reagent, the state of A549 cell is observed in the back under laser confocal microscope (LSCM), and it is green that living cells shows, and dead cell shows redness.
The result shows, people's pulmonary epithelial cells (A549) damage that baicalin can the bacterium alpha hemolysin mediation of protective money Portugal, and this effect presents dose dependent.
3. the experimental therapeutic research of mice gold Portugal bacterium pneumonia
3.1 mice gold Portugal bacterium pneumonia model
(male, 18-22g) behind etherization, per nasal gives 30 μ l gold Portugal's bacteria suspension (the golden bacterium 8325-4 of Portugal) to the C57BL/6J mice, and mice lies low until reviving, and sets up the model of mice gold Portugal bacterium pneumonia.The test that causes death is given with 4 * 10
8The golden Portugal bacterium of CFUs, and histopathology is investigated to 2 * 10
8The golden Portugal bacterium of CFUs.
3.2 protective rate test
The baicalin of 2h difference subcutaneous injection 100,50 and 25mg/kg (100 μ l) behind the mouse inoculation gold Portugal bacterium, every 6h is administered once.Not administration matched group is given the normal saline with 100 μ l, every group of 30 mices.By after the dosage regimen administration, write down the mouse infection gold bacterium 24h of Portugal respectively, 48h, the mortality rate behind the 72h.
The result shows, after baicalin is handled, significantly reduces the mortality rate (P＜0.05) of mice gold Portugal bacterium pneumonia.Like table 2.
Table 2. baicalin is to the influence of mice gold Portugal bacterium pneumonia mortality rate
Claims (4)
1. the application of baicalin in preparation treatment pneumonia medicine.
2. medicine comprises pharmaceutically acceptable dosage form according to claim 1.
3. pneumonia refers to bacterial pneumonia and fungal pneumonia according to claim 1.
4. be meant the pneumonia that causes by staphylococcus aureus like the said bacterial pneumonia of claim 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103707203A CN102429899A (en) | 2011-11-21 | 2011-11-21 | Application of baicalein to preparation of medicament for treating pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103707203A CN102429899A (en) | 2011-11-21 | 2011-11-21 | Application of baicalein to preparation of medicament for treating pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102429899A true CN102429899A (en) | 2012-05-02 |
Family
ID=45978488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103707203A Pending CN102429899A (en) | 2011-11-21 | 2011-11-21 | Application of baicalein to preparation of medicament for treating pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102429899A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755311A (en) * | 2012-07-05 | 2012-10-31 | 吉林大学 | Application of oroxylin A in preparing medicament for treating pneumonia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519236A (en) * | 2003-09-01 | 2004-08-11 | ƽ | Compound of flavonoid as well as application and dosage form of extract product of the compound |
| CN1606979A (en) * | 2003-10-16 | 2005-04-20 | 车庆明 | Effect of scutellarein as antifebrile, analgesic, antiphlogistic, antibiotic and antiviral agent |
| CN101716171A (en) * | 2009-11-02 | 2010-06-02 | 苏州中药研究所 | Application of scutellarin extract in preparation medicaments for preventing and treating pulmonary fibrosis |
-
2011
- 2011-11-21 CN CN2011103707203A patent/CN102429899A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519236A (en) * | 2003-09-01 | 2004-08-11 | ƽ | Compound of flavonoid as well as application and dosage form of extract product of the compound |
| CN1606979A (en) * | 2003-10-16 | 2005-04-20 | 车庆明 | Effect of scutellarein as antifebrile, analgesic, antiphlogistic, antibiotic and antiviral agent |
| CN101716171A (en) * | 2009-11-02 | 2010-06-02 | 苏州中药研究所 | Application of scutellarin extract in preparation medicaments for preventing and treating pulmonary fibrosis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755311A (en) * | 2012-07-05 | 2012-10-31 | 吉林大学 | Application of oroxylin A in preparing medicament for treating pneumonia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103385912B (en) | Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus | |
| CN105412131A (en) | Application of verbascoside in preparation of pneumonia treatment drug | |
| CN103191100A (en) | Application of puerarin in preparation of drug for treating pneumonia | |
| CN102872004B (en) | Application of the naringenin in treatment pneumonia medicine is prepared | |
| CN102727509A (en) | Application of baicalin to preparation of medicament for treating pneumonia | |
| CN102429899A (en) | Application of baicalein to preparation of medicament for treating pneumonia | |
| CN102755311A (en) | Application of oroxylin A in preparing medicament for treating pneumonia | |
| CN102872003B (en) | Application of the apiolin in treatment pneumonia medicine is prepared | |
| CN102872005B (en) | Application of the glycyrrhizin in treatment pneumonia medicine is prepared | |
| CN106668100B (en) | Application of Babaodan in preparing medicament for treating meningitis | |
| CN105193784B (en) | Application of the ginkgetin in preparation treatment streptococcus suis infection drug | |
| CN107714678A (en) | Application of the pterostilbene in the enzyme inhibitors of MCR 1 are prepared | |
| CN109464439A (en) | Osthole is preparing the application in MCR-1 enzyme inhibitor | |
| CN115300521A (en) | Application of narirutin in preparation of Sortase A sortase and PLY hemolysin inhibitor | |
| CN106474141A (en) | Osthole is combined application in preparation treatment pneumonia medicine for the baicalin | |
| CN111053764B (en) | Application of salvianolic acid A in preparation of medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia | |
| CN106265630A (en) | Amentoflavone application in research and development treatment pneumonia medicine | |
| CN103479659A (en) | Application of three kinds of oroxin in preparing drug for resisting staphylococcus aureus infection | |
| CN102755313A (en) | Application of silibinin in preparation of medicament for treating pneumonia | |
| CN103191099B (en) | The application in anti-listeria infection medicine prepared by fisetin | |
| CN103622984A (en) | Application of baicalin in preparation of medicine for treating acute hemolytic uremic syndrome | |
| CN113440521B (en) | Application of patchoulenone in preparation of MCR-1 enzyme inhibitor | |
| CN106667996B (en) | Morin is preparing the application in anti-streptococcus suis medicine | |
| CN1331535C (en) | Application of viscid serratia vaccine in preparing medicine for treating bronchial asthma | |
| CN103520323B (en) | Application of Nauclea officinalis extract to preparation of medicament for resisting methicillin-resistant Staphylococcus aureus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120502 |